Scarica l'app Stockscreener
2.48
3.77%
0.09
Dopo l'orario di chiusura:
2.44
-0.04
-1.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Cantor Fitzgerald - Defense World
Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in January - Defense World
Aclaris Therapeutics forms new Scientific Advisory Board - MSN
StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewswire
Aclaris Therapeutics forms new Scientific Advisory Board By Investing.com - Investing.com Nigeria
Aclaris Therapeutics Appoints Marianne Mann and Zuzana Diamant to Scientific Advisory Board - citybiz
Assenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Cantor Fitzgerald Comments on ACRS FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ACRS FY2025 Earnings - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in December - MarketBeat
Hair Treatment Drug Market Is Booming Worldwide | 3S Bio, Inc.,AbbVie,Aclaris Therapeutics, Inc.,Cipla, Inc. - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.00 Average Target Price from Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jane Street Group LLC - MarketBeat
Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Highlights Drug Progress and Financial Strength - TipRanks
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Hair Loss Treatment Market Is Booming Worldwide 2024-2031 | Viviscal, Cipla Inc., Aclaris Therapeutics - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by State Street Corp - Defense World
Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences - MSN
HC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS) - MSN
ACRS LOSS NOTICE: ROSEN, A LEADING FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the FirmACRS - AccessWire
INVESTOR ALERTAclaris Therapeutics, Inc. (ACRS)Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 - AccessWire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 27.4% in December - MarketBeat
Research Analysts Issue Forecasts for ACRS FY2024 Earnings - Defense World
HC Wainwright Has Bullish Estimate for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma - Investing.com Nigeria
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma By Investing.com - Investing.com South Africa
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Buy at HC Wainwright - Defense World
HighTower Advisors LLC Trims Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday - Benzinga
Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls - Nasdaq
HC Wainwright Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to "Buy" - MarketBeat
Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $8.80 - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $8.80 - MarketBeat
Fmr LLC Cuts Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World
0.69%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):